Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 11 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2019OBI-3424, a novel AKR1c3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALLEvans, K.; Duan, J.X.; Pritchard, T.; Jones, C.D.; McDermott, L.; Gu, Z.; Toscan, C.E.; El-Zein, N.; Mayoh, C.; Erickson, S.W.; Guo, Y.; Meng, F.; Jung, D.; Rathi, K.S.; Roberts, K.G.; Mullighan, C.G.; Shia, C.S.; Pearce, T.; Teicher, B.A.; Smith, M.A.; et al.
2019International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine gliomaTsoli, M.; Shen, H.; Mayoh, C.; Franshaw, L.; Ehteda, A.; Upton, D.; Carvalho, D.; Vinci, M.; Meel, M.H.; van Vuurden, D.; Plessier, A.; Castel, D.; Drissi, R.; Farrell, M.; Cryan, J.; Crimmins, D.; Caird, J.; Pears, J.; Francis, S.; Ludlow, L.E.A.; et al.
2021ELOVL5 is a critical and targetable fatty acid elongase in prostate cancerCentenera, M.M.; Scott, J.S.; Machiels, J.; Nassar, Z.D.; Miller, D.C.; Zinonos, I.; Dehairs, J.; Burvenich, I.J.G.; Zadra, G.; Chetta, P.; Bango, C.; Evergren, E.; Ryan, N.K.; Gillis, J.L.; Mah, C.Y.; Tieu, T.; Hanson, A.R.; Carelli, R.; Bloch, K.; Panagopoulos, V.; et al.
2019Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemiaMoujalled, D.M.; Pomilio, G.; Ghiurau, C.; Ivey, A.; Salmon, J.; Rijal, S.; Macraild, S.; Zhang, L.; Teh, T.C.; Tiong, I.S.; Lan, P.; Chanrion, M.; Claperon, A.; Rocchetti, F.; Zichi, A.; Kraus-Berthier, L.; Wang, Y.; Halilovic, E.; Morris, E.; Colland, F.; et al.
2016Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic targetAsim, M.; Massie, C.; Orafidiya, F.; Pértega-Gomes, N.; Warren, A.; Esmaeili, M.; Selth, L.; Zecchini, H.; Luko, K.; Qureshi, A.; Baridi, A.; Menon, S.; Madhu, B.; Escriu, C.; Lyons, S.; Vowler, S.; Zecchini, V.; Shaw, G.; Hessenkemper, W.; Russell, R.; et al.
2013Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcriptionThomas, D.; Powell, J.; Vergez, F.; Segal, D.; Nguyen, N.; Baker, A.; Teh, T.; Barry, E.; Sarry, J.; Lee, E.; Nero, T.; Jabbour, A.; Giovanna, P.; Green, B.; Manenti, S.; Glaser, S.; Parker, M.; Lopez, A.; Ekert, P.; Lock, R.; et al.
2019Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemiaBell, C.C.; Fennell, K.A.; Chan, Y.C.; Rambow, F.; Yeung, M.M.; Vassiliadis, D.; Lara, L.; Yeh, P.; Martelotto, L.G.; Rogiers, A.; Kremer, B.E.; Barbash, O.; Mohammad, H.P.; Johanson, T.M.; Burr, M.L.; Dhar, A.; Karpinich, N.; Tian, L.; Tyler, D.S.; MacPherson, L.; et al.
2021CDK4/6 inhibition promotes antitumor immunity through the induction of T-cell memoryLelliott, E.J.; Kong, I.Y.; Zethoven, M.; Ramsbottom, K.M.; Martelotto, L.G.; Meyran, D.; Zhu, J.J.; Costacurta, M.; Kirby, L.; Sandow, J.J.; Lim, L.; Dominguez, P.M.; Todorovski, I.; Haynes, N.M.; Beavis, P.A.; Neeson, P.J.; Hawkins, E.D.; McArthur, G.A.; Parish, I.A.; Johnstone, R.W.; et al.
2018Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapyMarini, K.D.; Croucher, D.R.; McCloy, R.A.; Vaghjiani, V.; Gonzalez-Rajal, A.; Hastings, J.F.; Chin, V.; Szczepny, A.; Kostyrko, K.; Marquez, C.; Samantha, W.; Jayasekara, N.; Alamgeer, M.; Boolell, V.; Han, J.Z.R.; Waugh, T.; Lee, H.C.; Oakes, S.R.; Kumar, B.; Harrison, C.A.; et al.
2015Progesterone receptor modulates ERα action in breast cancerMohammed, H.; Russell, I.; Stark, R.; Rueda, O.; Hickey, T.; Tarulli, G.; Serandour, A.; Birrell, S.; Bruna, A.; Saadi, A.; Menon, S.; Hadfield, J.; Pugh, M.; Raj, G.; Brown, G.; D'Santos, C.; Robinson, J.; Silva, G.; Launchbury, R.; Perou, C.; et al.